Dawson James Sticks to Its Buy Rating for Citius Pharmaceuticals (CTXR)

By Carrie Williams

In a report issued on February 18, Jason Kolbert from Dawson James maintained a Buy rating on Citius Pharmaceuticals (CTXRResearch Report), with a price target of $6.00. The company’s shares closed last Wednesday at $2.22.

According to TipRanks.com, Kolbert has 0 stars on 0-5 stars ranking scale with an average return of -3.0% and a 39.3% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as Sorrento Therapeutics, Anavex Life Sciences, and ADiTx Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Citius Pharmaceuticals with a $6.00 average price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $2.90 and a one-year low of $0.42. Currently, Citius Pharmaceuticals has an average volume of 9.6M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Citius Pharmaceuticals, Inc. engages in the development and commercialization of therapeutic products. It offers Mino-Lok, a patented solution to treat and salvage infected central venous catheters in patients with catheter related bloodstream infections and Hydro-Lido, a topical formulation of hydrocortisone and lidocaine that is intended for treatment of hemorrhoids. The company was founded by Ralph Montrone on January 23, 2007 and is headquartered in Cranford, NJ.